Tanvex BioPharma, Inc. announced that on March 3, 2023, the board of directors of the company approved Peter K.H. Lin, chief financial officer, as the agent in charge of accounting officer. Effective date is March 3, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39 TWD | +1.17% | +5.55% | -40.09% |
05-28 | Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index | CI |
03-14 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-40.09% | 196M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- 6541 Stock
- News Tanvex BioPharma, Inc.
- Tanvex BioPharma, Inc. Appoints Peter K.H. Lin as Agent in Charge of Accounting Officer